MLL gene alterations in radiation-associated acute myeloid leukemia

Experimental Oncology

Volumn 27, Issue 1, 2005, Pages 71-75

  Klymenko, Sergiy V ^a   Bink, Karin ^b   Trott, Klaus R ^c   Bebeshko, Vladimir G ^a   Bazyka, Dimitry A ^a   Dmytrenko, Iryna V ^a   Abramenko, Iryna V ^a   Bilous, Nadia I ^a   Zitzelsberger, Horst ^b   Misurin, Andrei V ^d   Atkinson, Michael J ^b   Rosemann, Michael ^b  

^a STATE INSTITUTION NATIONAL RESEARCH CENTER FOR RADIATION MEDICINE OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE   (Ukraine)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c Gray Cancer Institute   (United Kingdom)

^d NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

Author keywords

Acute myelogenous leukemia; Chernobyl accident; Duplication; Ionizing radiation; MLL; Translocation

Indexed keywords

GYRASE INHIBITOR; MIXED LINEAGE LEUKEMIA PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CHERNOBYL ACCIDENT; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DUPLICATION; GENE MUTATION; GENE REARRANGEMENT; GENE TRANSLOCATION; HODGKIN DISEASE; HUMAN; IONIZING RADIATION; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; RADIATION EXPOSURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; CHERNOBYL NUCLEAR ACCIDENT; CHROMOSOME ABERRATIONS; DNA, NEOPLASM; DNA-BINDING PROTEINS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MYELOID-LYMPHOID LEUKEMIA PROTEIN; PROTO-ONCOGENES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS;

EID: 20244390471     PISSN: 02043564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Di Martino JF, Cleary ML. MLL rearrangements in haematological malignancies: lessons from the clinical and biological studies. Br J Haematol 1999; 106: 614-26.
2. Ayton PM, Cleary ML. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 2001; 20: 5695-707.
3. Armstrong SA, Staunton JE, Silverman LD, Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD, Sallan SE, Lander ES, Golub TR, Korsmeyer SJ. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002; 30: 41-7.
4. Schoch C, Schnittger S, Klaus M, Kern W, Hiddemann W, Haferlach T. AML with 11q23/MLL abnormalities as defined by the WHO-classification: Incidence, partner chromosomes, FAB-subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML. Blood 2003; 102: 2395-402.
5. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 2000; 36: 69-86.
6. Mitterbauer-Hohendanner G, Mannhalter C. The biological and clinical significance of MLL abnormalities in haematological malignancies. Eur J Clin Invest 2004; 34: 12-24.
7. Leone G, Mele L, Pulsoni A, Equitani F, Pagano L. The incidence of secondary leukemias. Haematologica 1999; 84: 937-45.
8. Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 2004; 18: 120-5.
9. Olney HJ, Mitelman F, Johansson B, Mrozek K, Berger R, Rowley JD. Unique balanced chromosome abnormalities in treatment-related myelodysplastic syndromes and acute myeloid leukemia: report from an international workshop. Genes Chromosomes Cancer 2002; 33: 413-23.
10. Ng A, Taylor GM, Eden OB. Treatment-related leukaemia - a clinical and scientific challenge. Cancer Treat Rev 2000; 26: 377-91.
11. Pedersen-Bjergaard J, Philip P, Larsen SO, Andersson M, Daugaard G, Ersboll J, Hansen SW, Hou-Jensen K, Nielsen D, Sigsgaard TC, Specht L, Osterlind K. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia 1993; 7: 1975-86.
12. Bloomfield CD, Archer KJ, Mrozek K, Lillington DM, Kaneko Y, Head DR, Dal Cin P, Raimondi SC. 11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002; 33: 362-78.
13. Dann EJ, Rowe JM. Biology and therapy of secondary leukaemias. Best Pract Res Clin Haematol 2001; 14: 119-37.
14. Takeyama K, Seto M, Uike N, Hamajima N, Ino T, Mikuni C, Kobayashi T, Maruta A, Muto Y, Maseki N, Sakamaki H, Saitoh H, Shimoyama M, Ueda R. Therapy-related leukemia and myelodysplastic syndrome: a large-scale Japanese study of clinical and cytogenetic features as well as prognostic factors. Int J Hematol 2000; 71: 144-52.
15. Chumack VV, Bakhanova EV, Musiyachenko NV, Sholom SV, Pasalskaja LF. Dosimetry of liquidators in 14 years after the Chernobyl accident: problems and accomplishments. Int J Radiat Med 2000; 1: 26-45.
16. Ilyin IA, Krjuchkov VP, Osanov DP, Pavlov DA. Exposure levels for persons involved in recovery operations following the Chernobyl accident in 1986-1987 and dosimetric data verification. Radiats Biol Radioecol 1995; 35: 803-25.
17. Chumack VV, Likhtarev IA, Pavlenko JV. Monitoring of individual doses of populations residing in the territories contaminated after the Chernobyl accident. Radiat Prot Dosimetry 1999; 85: 137-9.
18. Likhtarev IA, Kovgan LN, Jacob P, Anspaugh LR. Chernobyl accident: retrospective and prospective estimates of external dose of the population of Ukraine. Health Phys 2002; 82: 290-303.
19. Chomchzynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.
20. Mrozek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev 2004; 18: 115-36.
21. Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, Vardiman JW, Rowley JD, Larson RA. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003; 102: 43-52.
22. Tanaka K, Arif M, Eguchi M, Kyo T, Dohy H, Kamada N. Frequent jumping translocations of chromosomal segments involving ABL oncogene alone or in combination with CD3-MLL genes in secondary leukemias. Blood 1997; 89: 596-600.
23. Reddy KS, Parsons L, Mak L, Dighe P, Saphner T, Crow MK, Scott M. Segmental amplification of 11q23 region identified by fluorescence in situ hybridization in four patients with myeloid disorders: a review. Cancer Genet Cytogenet 2001; 126: 139-46.
24. Andersen MK, Christiansen DH, Kirchhoff M, Pedersen-Bjergaard J. Duplication or amplification of chromosome band I1q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and AML, and is closely related to mutation of the TP53 gene and to previous therapy with alkylating agents. Genes Chromosomes Cancer 2001; 31: 33-41.
25. Michaux L, Wlodarska I, Stul M, Dierlamm J, Mugneret F, Herens C, Beverloo B, Verhest A, Verellen-Dumoulin C, Verhoef G, Selleslag D, Madoe V, Lecomte M, Deprijck B, Ferrant A, Delannoy A, Marichal S, Duhem C, Dicato M, Hagemeijer A. MLL amplication in myeloid leukemias: a study of 14 cases with multiple copies of 11q23. Genes Chromosomes Cancer 2000; 29: 40-7.